Your browser doesn't support javascript.
loading
A randomised phase I study of etrolizumab (rhuMAb ß7) in moderate to severe ulcerative colitis.
Rutgeerts, Paul J; Fedorak, Richard N; Hommes, Daan W; Sturm, Andreas; Baumgart, Daniel C; Bressler, Brian; Schreiber, Stefan; Mansfield, John C; Williams, Marna; Tang, Meina; Visich, Jennifer; Wei, Xiaohui; Keir, Mary; Luca, Diana; Danilenko, Dimitri; Egen, Jackson; O'Byrne, Sharon.
Afiliación
  • Rutgeerts PJ; Department of Medicine, Division of Gastroenterology, University of Leuven, Herestraat 49, 3052 Leuven, Belgium. paul.rutgeerts@uz.kuleuven.ac.be
Gut ; 62(8): 1122-30, 2013 Aug.
Article en En | MEDLINE | ID: mdl-22717454

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fármacos Gastrointestinales / Colitis Ulcerosa / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2013 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fármacos Gastrointestinales / Colitis Ulcerosa / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2013 Tipo del documento: Article